Effect of Weight and/or Obesity on Sulfamethoxazole and Trimethoprim Concentrations
Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
This study will find how weight affects the dosing of a drug called sulfamethoxazole and
trimethoprim. Currently, the amount of sulfamethoxazole and trimethoprim a patient receives
is the same regardless of the patient's weight. The entire cohort was analyzed for the study
outcomes. BMI groups were for recruitment purposes only and were not used for ordinal data
analysis.
All sulfamethoxazole and trimethoprim (Trade name is Bactrim or Septra) medication that you
will receive in this study will be referred to as study medication within this informed
consent form. This drug is a combination of two antibiotics, sulfamethoxazole and
trimethoprim, which belongs to a class of medication known as "sulfones" and is approved by
the US Food and Drug Administration (FDA) for the treatment of a wide variety of bacterial
infections such as ear infections, urinary tract infections, bronchitis, traveler's diarrhea,
and Pneumocystis carinii pneumonia. Sulfamethoxazole and trimethoprim is given orally.
Phase:
Phase 4
Details
Lead Sponsor:
Texas Tech University Health Sciences Center
Collaborators:
National Center for Research Resources (NCRR) University of Texas Southwestern Medical Center
Treatments:
Sulfamethoxazole Trimethoprim Trimethoprim, Sulfamethoxazole Drug Combination